Alcolase

Alcolase is a Danish biotech company developing enzyme-based technology for alcohol intolerance. The company’s first product is designed to help break down alcohol in the stomach before it is absorbed into the bloodstream. This addresses a hidden global health problem affecting around 540 million people, primarily in East Asia, who live with ALDH2 deficiency; a genetic variant that makes it difficult for the body to break down alcohol effectively and can lead to flushing, nausea, discomfort and increased health risks associated with alcohol consumption.

Alcolase’s solution is built around a liposomal encapsulation platform that protects enzymes from stomach acid and keeps them active where they are needed. The company is initially focused on alcohol intolerance, where the ambition is to give people a healthier alternative and a real choice in how they participate in social and cultural life. Over time, the platform may also have potential in broader therapeutic use cases, with the company expanding its activities through a UK subsidiary.

Alcolase is a research-driven company based in Copenhagen. The team is led by CEO & Co-founder Mikkel Precht, COO & Co-founder Ib Christensen and CSO Henrik Almdal, who combine biotechnology, scale-up experience and scientific expertise. Together, they are building a company focused on using biology to solve an overlooked problem affecting millions of people’s everyday lives.

Key facts

• Danish biotech company
• Enzyme-based technology for alcohol intolerance
• First product focused on people living with ALDH2 deficiency
• Liposomal encapsulation platform designed to protect enzymes in the stomach
• Based in Copenhagen with a therapeutic subsidiary in the UK

Team

• Mikkel Precht, CEO & Co-founder
• Ib Christensen, COO & Co-founder
• Henrik Almdal, CSO